Vital Therapies Announces Fourth Quarter and Full Year 2014 Financial Results and Provides a Corporate Update
March 19, 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, March 19, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...
Vital Therapies Announces Fourth Quarter and Full Year 2014 Financial Results Conference Call With Webcast
March 05, 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, March 5, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, will...
Vital Therapies Announces VTI-208 Phase 3 Clinical Trial Reaches Enrollment Target
January 30, 2015 08:00 ET
|
Vital Therapies, Inc.
- ON TRACK FOR RELEASE OF TOPLINE DATA IN THE SECOND QUARTER OF 2015 -
- 200 PATIENTS ENROLLED -
SAN DIEGO, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a...
Vital Therapies Provides Clinical and Regulatory Update
January 12, 2015 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, today...
Vital Therapies Announces First Subject Enrolled in VTI-210 and Provides Update on Enrollment in VTI-208
December 08, 2014 08:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, today...
Vital Therapies Expands Management Team
November 20, 2014 08:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure,...
Vital Therapies Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
November 13, 2014 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, today...
Vital Therapies Announces Third Quarter 2014 Financial Results Conference Call With Webcast and Upcoming Conference Presentation
October 30, 2014 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting treatment of acute liver failure, will...
Vital Therapies Announces Pricing of Follow-On Offering
October 02, 2014 22:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...
Vital Therapies Announces Launch of Proposed Follow-On Offering
September 30, 2014 16:08 ET
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure,...